Clinical Trial Confirms Safety of JW Pharmaceutical’s New Leukemia Drug
Clinical Trial Confirms Safety of JW Pharmaceutical’s New Leukemia Drug
  • By Lee Jun-sung (jslee@koreaittimes.com)
  • 승인 2016.05.03 11:46
  • 댓글 0
이 기사를 공유합니다

South Korean drug manufacturer JW Pharmaceutical has completed a Phase I clinical trial of CWP 291, a new drug developed for the treatment of various cancers including acute myeloid leukemia.

Judging that the safety of the drug has been sufficiently proven, JW Pharmaceutical now plans to move onto the next phase: expanding the use of the drug to treat other types of cancer, such as head and neck cancer and stomach cancer.
JW Pharmaceutical notified its shareholders on May 2 that 69 people with acute myeloid leukemia took the drug in its Phase I clinical trial of CWP 291 until December last year.

JW Pharmaceutical said: “The maximum tolerated dose (MTD) was determined in the Phase I clinical trial of CWP 291. The MTD was previously estimated at 100mg/m² in pre-clinical testing. The Phase I clinical trial, however, showed that the MTD was more than twice as high as the estimated 100mg/m². It was 250mg/m².”

The fact that the MTD well exceeded the estimated 100mg/m² indicates that the safety of the drug has been fully assured.

Backed by the results of the Phase I clinical trial of CWP 291, JW Pharmaceutical is now planning to expand the use of the drug to treat solid cancer like head and neck cancer, stomach cancer, ovarian cancer and breast cancer.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

  • ABOUT
  • CONTACT US
  • SIGN UP MEMBERSHIP
  • RSS
  • 2-D 678, National Assembly-daero, 36-gil, Yeongdeungpo-gu, Seoul, Korea (Postal code: 07257)
  • URL: www.koreaittimes.com | Editorial Div: 82-2-578- 0434 / 82-10-2442-9446 | North America Dept: 070-7008-0005 | Email: info@koreaittimes.com
  • Publisher and Editor in Chief: Monica Younsoo Chung | Chief Editorial Writer: Hyoung Joong Kim | Editor: Yeon Jin Jung
  • Juvenile Protection Manager: Choul Woong Yeon
  • Masthead: Korea IT Times. Copyright(C) Korea IT Times, All rights reserved.
ND소프트